GlassScriptPhysician profile
Joseph C Beaman
NPI 1366415705
$2,668.22
in general payments reported to CMS, 2019-2025
21 companies · $1,234 in 2025
The $1,234 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.06 · 2020: $22.62 · 2022: $28.01 · 2023: $329 · 2024: $1,041 · 2025: $1,234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,603.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $363.86 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $335.53 | 2022-2025 | |
| Novo Nordisk INC | $326.74 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $306.48 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Exact Sciences Corporation | $275.57 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $275.11 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $195.56 | 2023-2025 | Qulipta, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.72 | 2024-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $71.92 | 2024-2025 | Eliquis |
| Sanofi Pasteur INC. | $64.64 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $49.79 | 2025 | Austedo Xr |
| Phathom Pharmaceuticals, INC. | $48.37 | 2024 | Voquezna |
| Paratek Pharmaceuticals, INC. | $46.71 | 2024-2025 | Nuzyra |
| Merck Sharp & Dohme LLC | $39.62 | 2025 | Capvaxive, Gardasil 9, Enflonsia |
| Qiagen, LLC | $37.81 | 2024-2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $23.40 | 2025 | General - Pain Management |
| Eisai INC. | $18.48 | 2024 | |
| Tonix Medicines, INC. | $17.34 | 2025 | Tonmya |
| Neurocrine Biosciences, INC. | $16.47 | 2024 | Ingrezza |
| Actelion Pharmaceuticals US, INC. | $15.50 | 2024 | Uptravi, Opsumit |
| Amgen INC. | $13.60 | 2024 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Beaman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.